Cumberland Partners Ltd Purchases New Holdings in Pfizer Inc. (NYSE:PFE)

Cumberland Partners Ltd acquired a new position in shares of Pfizer Inc. (NYSE:PFEGet Rating) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 9,952 shares of the biopharmaceutical company’s stock, valued at approximately $588,000.

Other hedge funds also recently made changes to their positions in the company. Ibex Wealth Advisors acquired a new position in Pfizer in the 3rd quarter valued at $26,000. Econ Financial Services Corp acquired a new position in shares of Pfizer during the fourth quarter worth about $31,000. PYA Waltman Capital LLC purchased a new position in Pfizer during the fourth quarter worth about $31,000. TFO TDC LLC lifted its position in Pfizer by 126.9% in the fourth quarter. TFO TDC LLC now owns 667 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 373 shares during the period. Finally, MFA Wealth Advisors LLC acquired a new position in Pfizer during the 3rd quarter worth approximately $38,000. Institutional investors own 66.50% of the company’s stock.

Pfizer stock traded up $0.64 during trading on Tuesday, hitting $51.31. The company’s stock had a trading volume of 469,567 shares, compared to its average volume of 26,819,570. The stock’s fifty day moving average is $51.34 and its 200 day moving average is $52.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. Pfizer Inc. has a 1-year low of $38.47 and a 1-year high of $61.71. The stock has a market capitalization of $287.90 billion, a price-to-earnings ratio of 11.77, a P/E/G ratio of 0.60 and a beta of 0.76.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. During the same period in the prior year, the company earned $0.93 EPS. The company’s revenue was up 76.8% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 6.69 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Friday, May 13th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.12%. Pfizer’s dividend payout ratio is presently 36.70%.

In other news, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the sale, the senior vice president now owns 15,064 shares of the company’s stock, valued at $760,732. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

A number of research analysts recently weighed in on PFE shares. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating and set a $52.00 price objective on the stock. in a report on Tuesday, February 15th. JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a research note on Tuesday, May 3rd. Citigroup boosted their price objective on shares of Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a report on Tuesday, April 5th. Mizuho dropped their target price on shares of Pfizer from $56.00 to $55.00 in a report on Thursday, February 10th. Finally, Morgan Stanley initiated coverage on Pfizer in a report on Wednesday, April 6th. They issued an “equal weight” rating and a $55.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from, the company has a consensus rating of “Buy” and an average target price of $57.05.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.